Mylan Again Calls For An End To Authorized Generics During 180-Day Exclusivity Period
Mylan Inc."s (NASDAQ: MYL) Chief Operating Officer Heather Bresch today testified before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy concerning patent litigation settlements between branded pharmaceutical companies and generic pharmaceutical companies. During her testimony, Bresch conveyed Mylan"s position that the launch of an authorized generic by brand companies during a generic company"s 180-day exclusivity period undermines competition and delays timely access to high quality, affordable generic medications for patients, taxpayers, the government and businesses.
Endocrinology